Market
Story
FDA Approves Johnson & Johnson's Spravato Nasal Spray as First and Only Standalone Treatment for 21 Million US Adults with Depression
Jan 21, 2025, 06:44 PM
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first and only monotherapy for adults with treatment-resistant major depressive disorder (MDD). This approval allows the nasal spray to be used alone, marking a significant expansion from its previous approval, which required patients to be on other antidepressant medications. The FDA's decision is expected to benefit the estimated 21 million adults in the U.S. living with MDD who have not responded adequately to at least two oral antidepressants. Spravato has been administered to over 140,000 patients globally and has nearly six years of real-world data supporting its efficacy.
View original story
Similar markets
10% to 20% • 25%
More than 30% • 25%
20% to 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
More than 30% • 25%
20% to 30% • 25%
Less than 10% • 25%
Over 30% • 25%
11-20% • 25%
0-10% • 25%
21-30% • 25%
Top 15 • 25%
Top 5 • 25%
Top 10 • 25%
Below Top 15 • 25%
More than 80% • 25%
Less than 40% • 25%
40% to 60% • 25%
61% to 80% • 25%
More than $3 billion • 25%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
Eli Lilly • 25%
Pfizer • 25%
Other • 25%
AstraZeneca • 25%